Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a pioneering gene editing company, has reported a total of 45,461,310 shares and 51,531,339 voting rights as of June 30, 2021. The company is focused on developing innovative CAR-T immunotherapies for cancer treatment and therapeutic gene editing for various diseases. With over 21 years of expertise, Cellectis utilizes its proprietary technologies to advance hematological malignancies and blood disorders. It operates from its headquarters in Paris and additional locations in New York and Raleigh, with listings on both Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
06/30/2021	45,461,310	51,531,339

About Cellectis
Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomial storage diseases.

Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com   

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

IR contact:
Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, investors@cellectis.com 

Attachment

• Voting_Rights_PR_June_EN_docx

FAQ

What is the ticker symbol for Cellectis?

Cellectis is listed on Nasdaq under the ticker symbol CLLS.

What kind of therapies is Cellectis developing?

Cellectis is developing CAR-T immunotherapies for cancer and therapeutic gene editing for blood disorders.

How many shares did Cellectis have as of June 30, 2021?

As of June 30, 2021, Cellectis had 45,461,310 shares in capital.

How many voting rights does Cellectis have?

Cellectis had 51,531,339 voting rights as of June 30, 2021.

Where are Cellectis' headquarters located?

Cellectis is headquartered in Paris, France, with additional offices in New York and Raleigh.